Background: Schisandra chinensis is a traditional Chinese herbal medicine that has been used for centuries for liver health. The active lignans in Schisandra, including schisandrin and gomisins, have exhibited anti-inflammatory, antioxidant, and hepatoprotective properties in preliminary studies. With rising rates of chronic liver diseases globally, there is interest in the potential therapeutic role of Schisandra.
Purpose: To comprehensively review the current evidence for Schisandra chinensis in treating liver injury and disease and synthesize implications for future human research.
Main body: Schisandra extracts decreased inflammatory cytokines and oxidative stress markers and increased endogenous antioxidant activity in animal models, suggesting utility in mitigating liver inflammation and damage. Additional preclinical studies demonstrated attenuated liver enzyme levels, necrosis, and fibrosis progression in chemical-induced hepatotoxicity with Schisandra treatment. Enhanced cytochrome P450 activity, glutathione production, and glycogen synthesis were also observed, improving detoxification and regeneration capacity. Small human trials in hepatitis and nonalcoholic fatty liver disease showed improved liver enzymes and symptoms with Schisandra supplementation but were limited in quality and sample size.
Conclusion: Schisandra chinensis has biologically relevant mechanisms that warrant further human research on its role as a hepatoprotective phytotherapy. Well-designed, large-scale clinical trials are needed to establish efficacy and safety for liver disease applications.